Preoperative chemoradiotherapy for rectal cancer and impact on outcomes – A population-based study

Radiotherapy and Oncology

Volumn 123, Issue 3, 2017, Pages 446-453

  Åsli, Linn M ^a   Johannesen, Tom B ^a   Myklebust, Tor Å ^a   Møller, Bjørn ^a   Eriksen, Morten Tandberg ^b,c   Guren, Marianne Grønlie ^b  

^a CANCER REGISTRY OF NORWAY   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

Author keywords

Local recurrence; Population based; Preoperative chemoradiotherapy; Rectal cancer; Survival

Indexed keywords

CAPECITABINE; FLUOROURACIL;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGISTRY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CAUSE OF DEATH; CHEMORADIOTHERAPY; DISTANT METASTASIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME VARIABLE; PREOPERATIVE CARE; PREOPERATIVE RADIOTHERAPY; PRIORITY JOURNAL; RADICAL RESECTION; RADIOTHERAPY DOSAGE; RECTUM ABDOMINOPERINEAL RESECTION; RECTUM ANTERIOR RESECTION; RECTUM CANCER; RISK ASSESSMENT; SURGICAL MARGIN; TOTAL MESORECTAL EXCISION; TREATMENT OUTCOME; VERY ELDERLY; MORTALITY; MULTIMODALITY CANCER THERAPY; PREVENTION AND CONTROL; RECTUM TUMOR; TUMOR RECURRENCE;

AGED; AGED, 80 AND OVER; CHEMORADIOTHERAPY; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; RECTAL NEOPLASMS; TREATMENT OUTCOME;

EID: 85018739276     PISSN: 01678140     EISSN: 18790887     Source Type: Journal    
DOI: 10.1016/j.radonc.2017.04.012     Document Type: Article

References (43)

1. De Angelis, R., Sant, M., Coleman, M.P., et al. Cancer survival in Europe 1999–2007 by country and age: results of EUROCARE-5—a population-based study. Lancet Oncol 15 (2014), 23–34.
2. Glynne-Jones, R., Harrison, M., Hughes, R., Challenges in the neoadjuvant treatment of rectal cancer: balancing the risk of recurrence and quality of life. Cancer Radiother 17 (2013), 675–685.
3. Walters, S., Benitez-Majano, S., Muller, P., et al. Is England closing the international gap in cancer survival?. Br J Cancer 113 (2015), 848–860.
4. van den Broek, C.B., van Gijn, W., Bastiaannet, E., et al. Differences in pre-operative treatment for rectal cancer between Norway, Sweden, Denmark, Belgium and the Netherlands. Eur J Surg Oncol 40 (2014), 1789–1796.
5. van de Velde CJ, Boelens PG, Borras JM, et al. EURECCA colorectal: multidisciplinary management: European consensus conference colon & rectum. Eur J Cancer. 2014;50:1 e- e34.
6. Glimelius B, Tiret E, Cervantes A, Arnold D, Group EGW. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24 Suppl 6:vi81-8.
7. Lutz, M.P., Zalcberg, J.R., Glynne-Jones, R., et al. Second St. Gallen European Organisation for Research and Treatment of Cancer Gastrointestinal Cancer Conference: consensus recommendations on controversial issues in the primary treatment of rectal cancer. Eur J Cancer 63 (2016), 11–24.
8. Folkesson, J., Birgisson, H., Pahlman, L., Cedermark, B., Glimelius, B., Gunnarsson, U., Swedish rectal cancer trial: long lasting benefits from radiotherapy on survival and local recurrence rate. J Clin Oncol 23 (2005), 5644–5650.
9. van Gijn, W., Marijnen, C.A., Nagtegaal, I.D., et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol 12 (2011), 575–582.
10. Sauer, R., Liersch, T., Merkel, S., et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol 30 (2012), 1926–1933.
11. Hansen, M.H., Kjaeve, J., Revhaug, A., et al. Impact of radiotherapy on local recurrence of rectal cancer in Norway. Br J Surg 94 (2007), 113–118.
12. Bosset, J.F., Calais, G., Mineur, L., et al. Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study. Lancet Oncol 15 (2014), 184–190.
13. Tiefenthal, M., Nilsson, P.J., Johansson, R., Glimelius, B., Pahlman, L., The effects of short-course preoperative irradiation on local recurrence rate and survival in rectal cancer: a population-based nationwide study. Dis Colon Rectum 54 (2011), 672–680.
14. Norwegian Directorate of Health, Nasjonalt handlingsprogram med retningslinjer for diagnostikk, behandling og oppfølging av kreft i tykktarm og endetarm [National guidelines for diagnosis, treatment and follow up of cancer in colon and rectum]. 2015, Norwegian Directorate of Health, Oslo, Norway.
15. Guren, M.G., Korner, H., Pfeffer, F., et al. Nationwide improvement of rectal cancer treatment outcomes in Norway, 1993–2010. Acta Oncol 54 (2015), 1714–1722.
16. Eriksen, M.T., Wibe, A., Hestvik, U.E., Haffner, J., Wiig, J.N., Surgical treatment of primary locally advanced rectal cancer in Norway. Eur J Surg Oncol 32 (2006), 174–180.
17. Larsen, I.K., Smastuen, M., Johannesen, T.B., et al. Data quality at the Cancer Registry of Norway: an overview of comparability, completeness, validity and timeliness. Eur J Cancer 45 (2009), 1218–1231.
18. Åsli, L.M., Kvaløy, S.O., Jetne, V., et al. Utilization of radiation therapy in Norway after the implementation of the national cancer plan-a national, population-based study. Int J Radiat Oncol Biol Phys 90 (2014), 707–714.
19. Sakkestad, S.T., Olsen, B.C., Karliczek, A., Dahl, O., Pfeffer, F., Validity of Norwegian Rectal Cancer Registry data at a major university hospital 1997–2005. Acta Oncol 54 (2015), 1723–1728.
20. Wibe, A., Moller, B., Norstein, J., et al. A national strategic change in treatment policy for rectal cancer–implementation of total mesorectal excision as routine treatment in Norway. A national audit. Dis Colon Rectum 45 (2002), 857–866.
21. Braendengen, M., Tveit, K.M., Berglund, A., et al. Randomized phase III study comparing preoperative radiotherapy with chemoradiotherapy in nonresectable rectal cancer. J Clin Oncol 26 (2008), 3687–3694.
22. Eriksen, M.T., Wibe, A., Haffner, J., Wiig, J.N., Norwegian Rectal.Cancer, G., Prognostic groups in 1,676 patients with T3 rectal cancer treated without preoperative radiotherapy. Dis Colon Rectum 50 (2007), 156–167.
23. Aalen, O.O., Johansen, S., An empirical transition matrix for non-homogeneous Markov chains based on censored observations. Scand J Stat 5 (1978), 141–150.
24. Ederer F, Heise H. Instructions to IBM 650 programmers in processing survival computations. Methodological note no. 10. End Results Evaluation Section, National Cancer Institute. 1959.
25. Lambert, P.C., Royston, P., Further development of flexible parametric models for survival analysis 9 (2009), 265–290.
26. Bernstein, T.E., Endreseth, B.H., Romundstad, P., Wibe, A., Improved local control of rectal cancer reduces distant metastases. Colorectal Dis 14 (2012), e668–e678.
27. Taylor, F.G., Quirke, P., Heald, R.J., et al. Preoperative magnetic resonance imaging assessment of circumferential resection margin predicts disease-free survival and local recurrence: 5-year follow-up results of the MERCURY study. J Clin Oncol 32 (2014), 34–43.
28. Pettersson D, Lorinc E, Holm T, et al. Tumour regression in the randomized Stockholm III Trial of radiotherapy regimens for rectal cancer. Br J Surg. 2015;102:972–8; discussion 8.
29. White, I.R., Royston, P., Wood, A.M., Multiple imputation using chained equations: Issues and guidance for practice. Stat Med 30 (2011), 377–399.
30. Rubin, D.B., Multiple imputation for nonresponse in surveys. 1987, Wiley, New York.
31. StataCorp. Stata Statistical Software: Release 14. College Station, TX: StataCorp; 2015.
32. Nedrebo, B.S., Soreide, K., Eriksen, M.T., et al. Survival effect of implementing national treatment strategies for curatively resected colonic and rectal cancer. Br J Surg 98 (2011), 716–723.
33. Morris, E.J., Finan, P.J., Spencer, K., et al. Wide variation in the use of radiotherapy in the management of surgically treated rectal cancer across the english national health service. Clin Oncol (R Coll Radiol) 28 (2016), 522–531.
34. Elliot, A.H., Martling, A., Glimelius, B., Nordenvall, C., Johansson, H., Nilsson, P.J., Preoperative treatment selection in rectal cancer: a population-based cohort study. Eur J Surg Oncol 40 (2014), 1782–1788.
35. Joye, I., Silversmit, G., Van Eycken, E., et al. Survival among clinical stage I-III rectal cancer patients treated with different preoperative treatments: a population-based comparison. Cancer Epidemiol 43 (2016), 35–41.
36. Glimelius, B., Myklebust, T.A., Lundqvist, K., Wibe, A., Guren, M.G., Two countries - two treatment strategies for rectal cancer. Radiother Oncol 121 (2016), 357–363.
37. Glimelius, B., Neo-adjuvant radiotherapy in rectal cancer. World J Gastroenterol 19 (2013), 8489–8501.
38. Ngan, S.Y., Preoperative treatment of locally advanced rectal cancer: assets and drawbacks of short course and long course in clinical practice. Semin Radiat Oncol 26 (2016), 186–192.
39. Rutten, H.J.T., den Dulk, M., Lemmens, V.E.P.P., van de Velde, C.J.H., Marijnen, C.A.M., Controversies of total mesorectal excision for rectal cancer in elderly patients. Lancet Oncol 9 (2008), 494–501.
40. Pettersson, D., Holm, T., Iversen, H., Blomqvist, L., Glimelius, B., Martling, A., Preoperative short-course radiotherapy with delayed surgery in primary rectal cancer. Br J Surg 99 (2012), 577–583.
41. Breugom, A.J., Swets, M., Bosset, J.F., et al. Adjuvant chemotherapy after preoperative (chemo)radiotherapy and surgery for patients with rectal cancer: a systematic review and meta-analysis of individual patient data. Lancet Oncol 16 (2015), 200–207.
42. Nilsson, P.J., van Etten, B., Hospers, G.A., et al. Short-course radiotherapy followed by neo-adjuvant chemotherapy in locally advanced rectal cancer–the RAPIDO trial. BMC Cancer, 13, 2013, 279.
43. Nur, U., Shack, L.G., Rachet, B., Carpenter, J.R., Coleman, M.P., Modelling relative survival in the presence of incomplete data: a tutorial. Int J Epidemiol 39 (2010), 118–128.